{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:25Z","timestamp":1792783465077,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Firenze","id":[{"id":"https:\/\/ror.org\/04jr1s763","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) in Italy is undergoing a dual transition: a decline in viral (HCV\/HBV) etiology following direct-acting antivirals (DAAs) and a rise in metabolic (MASLD\/MASH)-related disease. Concurrently, the deceased-donor pool is being reshaped by donation after circulatory death (DCD) and machine perfusion, and neoadjuvant immune checkpoint inhibition is emerging as a possible route to transplant eligibility. This work explores, through scenario-based quantitative projections, how these forces may reshape the balance between hepatic resection and liver transplantation (LT) for HCC in Italy through 2035. This is a strategic framework supported by quantitative scenario projections, not a fully executed patient-level modelling study. Aggregate published data and registry annual reports (Piano Nazionale Esiti [PNE]; Centro Nazionale Trapianti [CNT]; European Liver Transplant Registry [ELTR]; ITA.LI.CA) and peer-reviewed literature were used; direct patient-level access to PNE and CNT datasets was not obtained. A deterministic scenario framework (conservative, baseline, expanded) was applied over 2027\u20132035. DCD growth was modelled with a saturating (logistic) function with an explicit carrying capacity. An explicit allocation layer bounds the HCC share of grafts by historical Italian values and does not permit it to rise as competing non-HCC demand grows. Immunotherapy-driven downstaging was parameterized from published neoadjuvant response data and treated as a promising but still-evolving input. Each headline output is reported with a scenario-based plausible range. Under the baseline scenario, total liver graft availability is projected to increase by \u224816\u201317% by 2035 (scenario range +11% to +23%), driven principally by a logistic rise in DCD activity toward \u2248450 liver transplants\/year (expanded corner \u2248600\/year) and by improved marginal-graft utilization via machine perfusion. Projected HCC incidence is broadly stable-to-declining overall, with a rising MASLD\/MASH -related fraction offsetting the viral-related decline. Because HCC has historically represented ~44\u201349% of Italian LT waitlistings, while non-HCC demand (alcohol-related disease, MASLD\/MASH, acute-on-chronic liver failure [ACLF]) is rising, the HCC share of grafts is constrained to ~45\u201350% in the scenario framework rather than assumed to expand; this yields \u22481,020\u20131,135 LT for HCC\/year even in the expanded scenario. Immunotherapy-driven conversion from unresectable to transplantable disease is modelled conservatively (15% conservative, ~18\u201324% baseline, 30% only as an optimistic sensitivity extreme). Net reallocation of highly selected early-stage cirrhotic patients from resection to transplantation is estimated at \u224811\u201315% of the reallocatable resection pool. Within the constraints of a finite, allocation-governed graft supply and rising competing demand, a modest, highly selective shift from resection toward transplantation in early-stage cirrhotic HCC is plausible but not automatic. Realizing it would require integrated national planning across transplant oncology, hepatobiliary surgery, donor-pool optimization, and centralization of complex care, together with prospective validation of immunotherapy-facilitated downstaging.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>The visual abstract details a predicted system-level shift in hepatocellular carcinoma (HCC) surgical management between 2027 and 2035. Causal factors include the etiological substitution from declining HCV-related HCC (via DAA therapies) to rising MASLD\/MASH-related HCC [Panel (1)], the method-driven expansion of the organ donor pool through DCD donation and machine perfusion [Panel (2)], and the therapy-driven expansion of patient candidacy via immunotherapy-driven downstaging to convert unresectable patients [Panel (3)]. These converging forces may produce a selective redistribution of curative-intent treatment pathways, characterized by increased LT volumes for HCC and a selective reallocation of some early-stage cirrhotic patients from HR to transplantation, while highlighting the potential need for greater centralization of complex care within high-volume centers [Panel (4)].<\/jats:p>","DOI":"10.1007\/s13304-026-02880-8","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:03:09Z","timestamp":1790611389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Future surgical strategies for hepatocellular carcinoma in Italy: a strategic framework and scenario-based projection of liver transplantation and hepatic resection from 2027 onwards"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3279-0313","authenticated-orcid":false,"given":"Gian Luca","family":"Grazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tirloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Risaliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"3","key":"2880_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/liv.14735","volume":"41","author":"F Garuti","year":"2021","unstructured":"Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M (2021) The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int 41(3):585\u2013597. https:\/\/doi.org\/10.1111\/liv.14735","journal-title":"Liver Int"},{"issue":"6","key":"2880_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/HEP.0000000000001644","volume":"83","author":"L Dove","year":"2026","unstructured":"Dove L, Chadha RM, Lai JC, DiMartini A, Liapakis A, Parikh ND, Firpi-Morell R, Conteh L, Fallon M, Trotter J, Ladner DP, Sapisochin G, Lucey MR (2026) AASLD AST practice guideline on adult liver transplantation: candidate evaluation. Hepatology 83(6):1609\u20131645. https:\/\/doi.org\/10.1097\/HEP.0000000000001644","journal-title":"Hepatology"},{"issue":"4","key":"2880_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/LVT.0000000000000688","volume":"32","author":"ZM Younossi","year":"2026","unstructured":"Younossi ZM, Germani G, Wong R, Stepanova M, Nader F, Karam V, Adam R, Alqahtani SA, Henry L, Burra P (2026) Steatotic liver disease is the dominant indication for liver transplantation in both Europe and the United States: trends and outcomes in the past 2 decades. Liver Transpl 32(4):549\u2013557. https:\/\/doi.org\/10.1097\/LVT.0000000000000688","journal-title":"Liver Transpl"},{"issue":"2","key":"2880_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","volume":"71","author":"D Haldar","year":"2019","unstructured":"Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, Feurstein B, Popp W, Karam V, Muiesan P, O\u2019Grady J, Jamieson N, Wigmore SJ, Pirenne J, Malek-Hosseini SA, Hidalgo E, Tokat Y, Paul A, Pratschke J, Bartels M, Trunecka P, Settmacher U, Pinzani M, Duvoux C, Newsome PN, Schneeberger S, European Liver and Intestine Transplant Association (ELITA) (2019) Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study. J Hepatol 71(2):313\u2013322. https:\/\/doi.org\/10.1016\/j.jhep.2019.04.011","journal-title":"J Hepatol"},{"key":"2880_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005792","author":"L Masiero","year":"2026","unstructured":"Masiero L, Procaccio F, Vespasiano F, Puoti F, Cardillo M, Feltrin G (2026) Is warm ischemic time no longer an absolute cutoff in organ donation after circulatory determination of death? The Italian experience of prolonged \u201cno-touch\u201d period. Transplantation. https:\/\/doi.org\/10.1097\/TP.0000000000005792","journal-title":"Transplantation"},{"issue":"1","key":"2880_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/LVT.0000000000000219","volume":"30","author":"D Ghinolfi","year":"2024","unstructured":"Ghinolfi D, Patrono D, De Carlis R, Melandro F, Buscemi V, Farnesi F, Torri F, Lauterio A, Di Salvo M, Cerchione R, Zanierato M, Morganti R, Romagnoli R, De Simone P, De Carlis L (2024) Liver transplantation with uncontrolled versus controlled DCD donors using normothermic regional perfusion and ex-situ machine perfusion. Liver Transpl 30(1):46\u201360. https:\/\/doi.org\/10.1097\/LVT.0000000000000219","journal-title":"Liver Transpl"},{"issue":"5","key":"2880_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jhep.2023.01.025","volume":"78","author":"J Eden","year":"2023","unstructured":"Eden J, Da Silva RX, Cortes-Cerisuelo M, Croome K, De Carlis R, Hessheimer AJ, Muller X, de Goeij F, Banz V, Magini G, Compagnon P (2023) Utilization of livers donated after circulatory death for transplantation\u2013an international comparison. J hepatol 78(5):1007\u20131016","journal-title":"J hepatol"},{"issue":"3","key":"2880_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","volume":"82","author":"P Tabrizian","year":"2025","unstructured":"Tabrizian P, Holzner ML, Ajmera V, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, Yao F, Florman SS, Schwartz ME, Mehta N (2025) Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study. J Hepatol 82(3):512\u2013522. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.003","journal-title":"J Hepatol"},{"key":"2880_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11648","volume":"36","author":"MPAW Claasen","year":"2023","unstructured":"Claasen MPAW, Sneiders D, Rakk\u00e9 YS, Adam R, Bhoori S, Cillo U, Fondevila C, Reig M, Sapisochin G, Tabrizian P, Toso C (2023) European Society of Organ Transplantation (ESOT) consensus report on downstaging, bridging and immunotherapy in liver transplantation for hepatocellular carcinoma. Transpl Int 36:11648. https:\/\/doi.org\/10.3389\/ti.2023.11648","journal-title":"Transpl Int"},{"issue":"3","key":"2880_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jhep.2021.10.024","volume":"76","author":"M Ravaioli","year":"2022","unstructured":"Ravaioli M, Lai Q, Sessa M, Ghinolfi D, Fallani G, Patrono D, Di Sandro S, Avolio A, Odaldi F, Bronzoni J, Tandoi F, De Carlis R, Pascale MM, Mennini G, Germinario G, Rossi M, Agnes S, De Carlis L, Cescon M, Romagnoli R, De Simone P (2022) Impact of MELD 30-allocation policy on liver transplant outcomes in Italy. J Hepatol 76(3):619\u2013627. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.024","journal-title":"J Hepatol"},{"issue":"10","key":"2880_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101720","volume":"17","author":"E Prosperi","year":"2025","unstructured":"Prosperi E, Cescon M, Lai Q, Bonatti C, Prosperi E, Rizzo F, Maroni L, Laurenzi A, Serenari M, Morelli MC, Ravaioli M (2025) The Italian score for organ allocation: a ten-year monocentric retrospective analysis in liver transplantation for hepatocellular carcinoma. Cancers (Basel) 17(10):1720. https:\/\/doi.org\/10.3390\/cancers17101720","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2880_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/joim.20051","volume":"297","author":"M Vidgren","year":"2025","unstructured":"Vidgren M, Delorme C, Oniscu GC (2025) Challenges and opportunities in organ donation after circulatory death. J Intern Med 297(2):124\u2013140. https:\/\/doi.org\/10.1111\/joim.20051","journal-title":"J Intern Med"},{"issue":"7","key":"2880_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306541","volume":"19","author":"S O'Neill","year":"2024","unstructured":"O\u2019Neill S, Thomas K, McLaughlin L, Boadu P, Williams L, Al-Haboubi M, Bostock J, Noyes J, Mays N (2024) Trends in organ donation in England, Scotland and Wales in the context of the COVID-19 pandemic and \u201copt-out\u201d legislation. PLoS ONE 19(7):e0306541. https:\/\/doi.org\/10.1371\/journal.pone.0306541","journal-title":"PLoS ONE"},{"key":"2880_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11697","volume":"36","author":"G Fallani","year":"2023","unstructured":"Fallani G, Stocco A, Siniscalchi A, Antonini MV, Stella AP, Amato A, Prosperi E, Turco L, Morelli MC, Cescon M, Ravaioli M (2023) Beyond the concepts of elder and marginal in DCD liver transplantation: a prospective observational matched-cohort study in the Italian clinical setting. Transpl Int 36:11697. https:\/\/doi.org\/10.3389\/ti.2023.11697","journal-title":"Transpl Int"},{"issue":"12","key":"2880_CR15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.dld.2022.08.033","volume":"54","author":"TM Manzia","year":"2022","unstructured":"Manzia TM, Trapani S, Nardi A, Ricci A, Lenci I, Milana M, Angelico R, De Feo TM, Agnes S, Andorno E, Baccarani U, Carraro A, Cescon M, Cillo U, Colledan M, De Carlis L, De Simone P, Di Benedetto F, Ettorre GM, Gruttadauria S, Lupo LG, Mazzaferro V, Romagnoli R, Rossi G, Rossi M, Spada M, Vennarecci G, Vivarelli M, Zamboni F, Tisone G, Cardillo M, Angelico M (2022) Temporal trends of waitlistings for liver transplantation in Italy: the ECALITA (Evolution of IndiCAtion in LIver transplantation in ITAly) registry study. Dig Liver Dis 54(12):1664\u20131671. https:\/\/doi.org\/10.1016\/j.dld.2022.08.033","journal-title":"Dig Liver Dis"},{"issue":"3","key":"2880_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2021.03.030","volume":"75","author":"LS Belli","year":"2021","unstructured":"Belli LS, Duvoux C, Artzner T, Bernal W, Conti S, Cortesi PA, Sacleux SC, Pageaux GP, Radenne S, Trebicka J, Fernandez J, Perricone G, Piano S, Nadalin S, Morelli MC, Martini S, Polak WG, Zieniewicz K, Toso C, Berenguer M, Iegri C, Invernizzi F, Volpes R, Karam V, Adam R, Faitot F, Rabinovich L, Saliba F, Meunier L, Lesurtel M, Uschner FE, Fondevila C, Michard B, Coilly A, Meszaros M, Poinsot D, Schnitzbauer A, De Carlis LG, Fumagalli R, Angeli P, Arroyo V, Jalan R, ELITA\/EF-CLIF working group (2021) Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA\/EF-CLIF collaborative study (ECLIS). J Hepatol 75(3):610\u2013622. https:\/\/doi.org\/10.1016\/j.jhep.2021.03.030","journal-title":"J Hepatol"},{"issue":"2","key":"2880_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jhep.2013.10.010","volume":"60","author":"A Vitale","year":"2014","unstructured":"Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U, Liver Transplantation North Italy Transplant program (NITp) working group (2014) A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 60(2):290\u2013297. https:\/\/doi.org\/10.1016\/j.jhep.2013.10.010","journal-title":"J Hepatol"},{"issue":"2","key":"2880_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1055\/s-0041-1723032","volume":"41","author":"B Moeckli","year":"2021","unstructured":"Moeckli B, Majno P, Orci LA, Peloso A, Toso C (2021) Liver transplantation selection and allocation criteria for hepatocellular carcinoma: a European perspective. Semin Liver Dis 41(2):172\u2013181. https:\/\/doi.org\/10.1055\/s-0041-1723032","journal-title":"Semin Liver Dis"},{"key":"2880_CR19","doi-asserted-by":"publisher","unstructured":"Parekh J, Abraham S, Andanamala H, et al. 2023 Neoadjuvant immunotherapy in hepatocellular carcinoma: a systematic review and meta-analysis. J Clin Oncol. 41(16suppl):e16232. https:\/\/doi.org\/10.1200\/JCO.2023.41.16suppl.e16232","DOI":"10.1200\/JCO.2023.41.16suppl.e16232"},{"issue":"16 suppl","key":"2880_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16suppl.e14624","volume":"43","author":"A Esmail","year":"2025","unstructured":"Esmail A, Abdelrahim M (2025) Immune checkpoint inhibitors as a neoadjuvant therapy pre-liver transplantation for hepatobiliary carcinoma. J Clin Oncol 43(16 suppl):e14624. https:\/\/doi.org\/10.1200\/JCO.2025.43.16suppl.e14624","journal-title":"J Clin Oncol"},{"issue":"8","key":"2880_CR21","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ajt.2026.02.024","volume":"26","author":"FR Ponziani","year":"2026","unstructured":"Ponziani FR, Giannelli V, Marrone G, Martini S, Morelli MC, Pagano D, Baroni GS, Germani G, Burra P, Toniutto P (2026) Expert consensus on the use of immune checkpoint inhibitors in the liver transplant setting: guidance from the Liver Transplant Committee of the Italian Association for the Study of the Liver (AISF). Am J Transplant 26(8):1946\u20131957. https:\/\/doi.org\/10.1016\/j.ajt.2026.02.024","journal-title":"Am J Transplant"},{"issue":"24","key":"2880_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14248871","volume":"14","author":"R Vella","year":"2025","unstructured":"Vella R, Pagano D, di Francesco F, Petri SL, Bonsignore P, Lorenzo ND, Calamia S, Tropea A, Vitale I, Vella I, Accardo C, Gelsomino S, Vieni S, Camm\u00e0 C, Ferrandelli G, Gruttadauria S (2025) Minimally invasive hepatic resection option for access to the waiting list of a single regional transplant center in Southern Italy: entry and dropout flows\u2019 analysis. J Clin Med 14(24):8871. https:\/\/doi.org\/10.3390\/jcm14248871","journal-title":"J Clin Med"},{"issue":"8","key":"2880_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15429","volume":"38","author":"C Lazzeri","year":"2024","unstructured":"Lazzeri C, Manuela B, Bagatti S, Antonelli S, Pane PL, Ghinolfi D, Peris A (2024) Tuscany normothermic regional perfusion mobile teams for controlled donation after circulatory death. Clin Transplant 38(8):e15429. https:\/\/doi.org\/10.1111\/ctr.15429","journal-title":"Clin Transplant"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-026-02880-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02880-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:14:23Z","timestamp":1790655263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-026-02880-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":23,"alternative-id":["2880"],"URL":"https:\/\/doi.org\/10.1007\/s13304-026-02880-8","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}